Homatropine Hydrobromide
Homatropine is a competitive muscarinic receptor antagonist with a bulky aromatic group in place of the acetyl group of acetylcholine. It is expected to act in similar manner as atropine, producing similar parasympatholytic effects. By blocking muscarinic receptors and cholinergic signalling pathways, homatropine blocks the response of the iris sphincter muscle and cause the pupil to become unresponsive to light upon dilation or mydriasis. It also blocks the accommodative muscle of the ciliary body to cholinergic stimulation.
For refraction: Instill two drops in the eye(s) and repeat 2-3 times at 5-10 minute intervals.For therapy: Instill 1-2 drops in the eye(s) every 3-4 hours.Use in children: Should not be used in children below the age of 3 months.
Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.
Contraindicated in patients with closed-angle glaucoma or with a narrow angle between the iris and the cornea.
Hypersensitivity may occur as conjunctivitis.
There are no adequate and well-controlled studies in pregnant women. Matropin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Homatropine is excreted in human milk. Caution should be exercised when Matropin is administered to a nursing mother.
Should be used with caution in patients with prostatic enlargement and in patients suffering from paralytic ileus or pyloric stenosis.
Mydriatic and Cycloplegic agents
Store in a cool & dry place, protect from light. Do not use longer than 30 days after first opening. Keep out of the reach of children.
{'Indications': 'Matropin eye drops is indicated for use as a mydriatic and cycloplegic.'}